CN118317780A - 脂肪肝和非酒精性脂肪肝炎的治疗药 - Google Patents
脂肪肝和非酒精性脂肪肝炎的治疗药 Download PDFInfo
- Publication number
- CN118317780A CN118317780A CN202280078804.6A CN202280078804A CN118317780A CN 118317780 A CN118317780 A CN 118317780A CN 202280078804 A CN202280078804 A CN 202280078804A CN 118317780 A CN118317780 A CN 118317780A
- Authority
- CN
- China
- Prior art keywords
- fatty liver
- amino acid
- peptide
- acid sequence
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Marine Sciences & Fisheries (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JPPCT/JP2021/036238 | 2021-09-30 | ||
| PCT/JP2021/036238 WO2023053384A1 (ja) | 2021-09-30 | 2021-09-30 | 脂肪肝および非アルコール性脂肪肝炎の治療薬 |
| PCT/JP2022/036662 WO2023054666A1 (ja) | 2021-09-30 | 2022-09-30 | 脂肪肝および非アルコール性脂肪肝炎の治療薬 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN118317780A true CN118317780A (zh) | 2024-07-09 |
Family
ID=85781770
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202280078804.6A Pending CN118317780A (zh) | 2021-09-30 | 2022-09-30 | 脂肪肝和非酒精性脂肪肝炎的治疗药 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240299496A1 (https=) |
| EP (1) | EP4410302A4 (https=) |
| JP (1) | JP7798300B2 (https=) |
| KR (1) | KR20240070640A (https=) |
| CN (1) | CN118317780A (https=) |
| AU (1) | AU2021466375A1 (https=) |
| CA (1) | CA3233234A1 (https=) |
| MX (1) | MX2024003974A (https=) |
| WO (2) | WO2023053384A1 (https=) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3358011T (pt) | 2011-04-26 | 2020-04-23 | Univ Osaka | Péptido para induzir a regeneração de um tecido e a sua utilização |
| US20200038486A1 (en) | 2017-04-07 | 2020-02-06 | StemRIM Inc. | Therapeutic medicine for fibrous disease |
| EP3728593A1 (en) * | 2017-12-18 | 2020-10-28 | Alnylam Pharmaceuticals, Inc. | High mobility group box-1 (hmgb1) irna compositions and methods of use thereof |
| US11684653B2 (en) * | 2019-03-06 | 2023-06-27 | The Cleveland Clinic Foundation | Compositions and method for reducing virulence of microorganisms |
-
2021
- 2021-09-30 AU AU2021466375A patent/AU2021466375A1/en active Pending
- 2021-09-30 CA CA3233234A patent/CA3233234A1/en active Pending
- 2021-09-30 WO PCT/JP2021/036238 patent/WO2023053384A1/ja not_active Ceased
- 2021-09-30 KR KR1020247014019A patent/KR20240070640A/ko active Pending
- 2021-09-30 JP JP2023550943A patent/JP7798300B2/ja active Active
-
2022
- 2022-09-30 MX MX2024003974A patent/MX2024003974A/es unknown
- 2022-09-30 EP EP22876529.3A patent/EP4410302A4/en active Pending
- 2022-09-30 WO PCT/JP2022/036662 patent/WO2023054666A1/ja not_active Ceased
- 2022-09-30 CN CN202280078804.6A patent/CN118317780A/zh active Pending
- 2022-09-30 US US18/697,330 patent/US20240299496A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20240299496A1 (en) | 2024-09-12 |
| EP4410302A1 (en) | 2024-08-07 |
| EP4410302A4 (en) | 2025-07-23 |
| AU2021466375A1 (en) | 2024-04-11 |
| KR20240070640A (ko) | 2024-05-21 |
| CA3233234A1 (en) | 2023-04-06 |
| WO2023054666A1 (ja) | 2023-04-06 |
| JPWO2023053384A1 (https=) | 2023-04-06 |
| WO2023053384A1 (ja) | 2023-04-06 |
| MX2024003974A (es) | 2024-07-09 |
| JP7798300B2 (ja) | 2026-01-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6634402B2 (ja) | 代謝障害及び疾患の治療のための組成物、使用及び方法 | |
| KR102607543B1 (ko) | 담즙산 항상성의 조절 및 담즙산 질환 및 질병의 치료 방법 | |
| JP6941321B2 (ja) | 疾患の要因となる生体内タンパク質を標的とするコンジュゲートワクチン | |
| US10716825B2 (en) | Method of treating a liver disease comprising administering ostreolysin orfunctionally related variant thereof | |
| JP2022516509A (ja) | 非アルコール性脂肪性肝疾患（ｎａｆｌｄ）を治療するための組成物および方法 | |
| TWI657821B (zh) | 用於治療ｃ－ｍｅｔ相關性癌症的方法和組成物 | |
| US11446376B2 (en) | Methods for treating heart failure using glucagon receptor antagonistic antibodies | |
| Jiang et al. | Attenuation of hepatic fibrosis through ultrasound-microbubble-mediated HGF gene transfer in rats | |
| Fang et al. | Gastrin attenuates sepsis-induced myocardial dysfunction by down-regulation of TLR4 expression in macrophages | |
| EP2744512A1 (en) | Use of neuregulin-4 for treatment of inflammatory bowel disease and necrotizing enterocolitis | |
| KR102174191B1 (ko) | 조직 재생 및 저하된 조직 기능의 회복을 자극하기 위한 제제로서의 디카르복시산의 비스아미드 유도체 | |
| CN118317780A (zh) | 脂肪肝和非酒精性脂肪肝炎的治疗药 | |
| HK40107111A (en) | Drug for treating fatty liver and non-alcoholic steatohepatitis | |
| CN101712960A (zh) | Mac-2BP肿瘤抗原基因、蛋白、抗体及其用途 | |
| EP1736168A1 (en) | Protease inhibitor and preventives or remedies for diseases | |
| CN111053889A (zh) | 三叶因子3及三叶因子3表达促进剂在制备预防治疗肝损伤药物中的应用 | |
| US20230201311A1 (en) | Compositions and methods for treating non-alcoholic steatohepatitis (nash) | |
| US20200061135A1 (en) | Method of treating overweight or obesity comprising administering a pleurotus ostreatus mushroom extract or a composition comprising a pleurotus ostretus mushroom extract | |
| US20210009672A1 (en) | Methods of treating or preventing liver fibrosis with inhibition of activins a & b | |
| US20190192458A1 (en) | Therapeutic/prophylactic agent for graft-versus-host disease, fibrocyte invasion inhibitor, and inhibitor against tear reduction and reduction in goblet cells | |
| CN119970730A (zh) | 哌啶酸在制备预防和/或治疗非酒精性脂肪性肝炎药物中的应用 | |
| HK40083624A (en) | Compositions and methods for treating non-alcoholic steatohepatitis (nash) | |
| Tanaka et al. | T1826 Vitamin K3 Attenuates Cerulein-Induced Pancreatitis via Inhibition Autophagy Pathway |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |